VEVA Building #14
Suite 200 1777 Sentry Parkway West
Blue Bell, PA 19422
United States
215-709-3040
http://www.achillion.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 56
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joseph Truitt | Pres, CEO & Director | 773.77k | N/A | 1965 |
| Mr. Paul Firuta | Exec. VP & COO | 462.03k | N/A | 1966 |
| Mr. Anthony S. Gibney | Exec. VP & Chief Bus. Officer | 408.66k | N/A | 1971 |
| Dr. Steven L. Zelenkofske | Exec. VP & Chief Medical Officer | 314.81k | N/A | 1959 |
| Mr. Brian R. Di Donato | CFO, SVP & Treasurer | N/A | N/A | 1967 |
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.